Vivet Therapeutics' Series A Round

Vivet Therapeutics raised a round of funding on May 04, 2017.

Vivet Therapeutics is a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases. Vivet's lead program, VTX801, is a novel investigational gene therapy for Wilson d…

Articles about Vivet Therapeutics' Series A Round: